ImageneBio, Inc.
corporate_fare Company Profile
ImageneBio, Inc. (NASDAQ:IMA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for IMA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for IMA spans 10-Q, S-3, 8-K, 424B3.
Recent high-impact activity:
- ImageneBio Q3 Loss Widens to $15.6M; Material Weakness Still Unremediated
- ImageneBio Registers $200M Shelf and Initiates $17M At-the-Market Program
- ImageneBio Posts $10.2M Q2 Loss, Holds $136.2M Cash, and Sets Clinical Timelines
- ImageneBio Q2 2026: $136.2M Cash Runway into 2028, Olevaprubart Phase 2b on Track
- ImageneBio Posts $10.2M Q2 Loss, Cash Runway Into 2028; Lead Drug Advances
Financial Snapshot
Short Interest & Short Volume
3.96 days to coverFINRA reported short interest of 45,958 shares in IMA as of the October 30, 2026 settlement, a 25.1% decrease from the prior period — about 4.0 days to cover at its recent average daily volume. On November 20, 2026, 0.3% of IMA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for IMA, detected from its recent SEC filings · based on capital-structure filings through 2026-08-05.
$200M Shelf Registration Filed · $17M ATM Program Launched
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →